CTX130

Serial Number 97635360
606

Registration Progress

Application Filed
Oct 17, 2022
Under Examination
Apr 23, 2024
Approved for Publication
Feb 7, 2024
Published for Opposition
Feb 27, 2024
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: CTX130
Previous Owner: CRISPR Therapeutics AG
Classes: 005, 042

Trademark Image

CTX130

Basic Information

Serial Number
97635360
Filing Date
October 17, 2022
Published for Opposition
February 27, 2024
Abandonment Date
December 2, 2024
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Dec 2, 2024
Classes
005 042

Rights Holder

CRISPR Therapeutics AG

99
Address
Baarerstrasse 14
ZUG V8 6300
CH

Ownership History

CRISPR Therapeutics AG

Original Applicant
99
ZUG V8 CH

CRISPR Therapeutics AG

Owner at Publication
99
ZUG V8 CH

Legal Representation

Attorney
Tiffany D. Gehrke

Application History

28 events
Date Code Type Description Documents
Dec 2, 2024 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Dec 2, 2024 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Dec 2, 2024 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Dec 2, 2024 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Apr 23, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 4, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 27, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 7, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 7, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 23, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 22, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 22, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 22, 2023 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Dec 22, 2023 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Dec 22, 2023 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Oct 2, 2023 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Oct 2, 2023 GNFR O FINAL REFUSAL E-MAILED Loading...
Oct 2, 2023 CNFR R FINAL REFUSAL WRITTEN Loading...
Sep 19, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 10, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 9, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 9, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 9, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 9, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
May 9, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 31, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 20, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 20, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Cells for medical or clinical use in the field of CAR T cell therapy for the treatment of hematologic malignancies; pharmaceutical and biopharmaceutical agents for the treatment of cancer in the field of CAR T cell therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer in the field of CAR T cell therapy
Class 042
Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of CAR T cell therapy for the treatment of hematologic malignancies; gene editing, namely, pharmaceutical research and development in the field of CAR T cell therapy for the treatment of hematologic malignancies

Classification

International Classes
005 042